Table 5.
Large registry datasets of infective endocarditis following TAVI. Studies with > 100 cases
| Publication | Location | N | Incidence |
Onset (months) |
Microorganisms (%) | Re-do surgery (%) | 1-year mortality (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Strep | Staph A | Entero | |||||||
|
Fauchier (2020) |
France | 47,553 | 1.89 | 13 | 29 | 16 | 23 | - | 33 |
|
Stortecky (2020) |
Switzerland | 7,203 | 1.0 | 7 | 29 | 22 | 26 | - | 37 |
|
Bjursten (2019) |
Sweden | 4,336 | 0.9 | - | 34 | 22 | 20 | 13 | 42 |
|
Butt (2019) |
Denmark | 2,632 | 1.6 | 12 | - | - | - | 4 | 40 |
|
Kolte (2018) |
United States | 29,306 | 1.7 | 2 | 30 | 22 | 21 | 0 | - |
|
Regueiro (2016) |
Europe, North and South America | 20,006 | 1.1 | 5 | 16 | 23 | 25 | 15 | - |
N number of TAVIs performed in each cohort, Incidence incidence of infective endocarditis following TAVI per 100 person-years, Onset time in months between TAVI and presentation with infective endocarditis, Microorganisms three most common microorganisms identified, Strep Streptococci, Staph A. Staphylococcus aureus, Entero Enterococcus, Re-do Surgery percentage rate of surgical intervention following diagnosis of TAVI-related IE